论文部分内容阅读
Objective: The aim of this study was to use network pharmacology to predict the targets and related signaling pathways of turmeric in the treatment of liver cancer. Methods: The active ingredients of turmeric turmeric and their corresponding targets were screened and collected through the traditional Chinese medicine components and systematic Chinese medicine pharmacology database and analysis platform (TCMSP) database. Through the online human Mendelian network (OMIM), the human genome annotation database (Genecards) and the GAD database, the targets related to liver cancer were collected and compared with the targets corresponding to the drug components, the common parts were screened out to obtain the potential target genes that overlap between turmeric and liver cancer. Cytoscape was used to construct the “compound - target” action network, and the protein interaction (PPI) network was constructed through STRING software to screen the key components and key targets of turmeric for the treatment of liver cancer, and the GO enrichment and KEGG enrichment analysis were conducted on the key targets to analyze their potential mechanism of action. Results: There were 15 active components and 45 target genes in the treatment of liver cancer with turmeric turmeric, and the drug-component-target-disease network showed that the key genes mainly included: MAPK1, MAPK3, AKT1, JUN, RELA, BCL2, CASP8, ESR1, ADRB2, etc. GO functional enrichment showed that biological processes and functions were concentrated in cofactor binding, phosphatase binding, amide binding, g-protein-coupled amide receptor activity, antioxidant activity, steroid activity, nuclear receptor activity, transcription factor activity, direct ligand regulation of sequence-specific DNA binding, and steroid hormone receptor activity. KEGG functional enrichment showed that the enriched pathways mainly included hepatitis b, human immunodeficiency virus 1 infection, apoptosis, hepatitis c and some cancer signaling pathways. Conclusion: The role of turmeric in the treatment of liver cancer may be realized through the above molecular mechanism, providing theoretical evidence for subsequent studies and clinical applications.